Clinical Trial Update: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab to ipilimumab as adjuvant therapy to prevent recurrence after complete resection of stage IIIb/c or stage IV melanoma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2021-06-15